The Swiss MS Skin Project was designed to determine the frequency of injection site reactions, including skin necrosis and lipoatrophy, in patients taking AVONEX, Betaferon, Copaxone, or Rebif (ABCRs). These data are important as ISRs are thought to reduce treatment compliance among patients. The study enrolled nearly 500 patients on ABCRs for a minimum of two years (mean treatment duration of 5.9 years) and followed patients for a total of one year. Study findings include:
The poster describing the study entitled 'An Evaluation of Adverse Skin Reactions in Patients with Multiple Sclerosis on Disease-Modifying Therapies' (P 787) is available for viewing on September 11, 2009 at 3:30pm local time.
Source: Eurekalert
LIN